A single dose novel coronavirus disease (Covid-19) vaccine of Gamaleya Research Institute of Epidemiology and Microbiology may soon become locally available, according to the Food and Drug Administration (FDA).
During the public address of President Rodrigo R. Duterte late Monday, FDA chief Eric Domingo disclosed the Russian pharmaceutical firm had informed them it is considering registering its Sputnik V vaccine as a single dose jab.
“We are waiting for the data to support this if it will be acceptable [to us],” Domingo said.
The Sputnik V currently makes use of two separate adenoviral jab to raise the resistance of a person against Covid-19.
The government has secured 10 million doses of Sputnik V jabs. Of which 180,000 doses have already arrived in the country.
Domingo said Gamaleya is now also considering amending its Emergency Use Authorization (EUA) of its Sputnik V to extend its interval time for a person to get his or her first and second dose of the said jab to 12 weeks.
If approved by FDA the interval time for getting the separate Sputnik V shots, which will now make it similar to the Covid-19 vaccine of AstraZeneca.